Company Overview and News

0
Paradigm Biopharmaceuticals completes recruitment for knee pain trial

2018-08-06 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has recruited 100% of participants for its phase IIb clinical trial evaluating injectable pentosan polysulfate sodium (iPPS).
PAR

0
Paradigm Biopharmaceuticals’ leaping share price attracts ASX speeding ticket

2018-07-09 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has attracted a speed and volume ticket from the ASX following an increase in its share price from a low of 72.5 cents to an intraday high of 90 cents on Friday.
PAR

0
Paradigm Biopharmaceuticals patients report over 50% pain reduction

2018-06-15 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received positive results from 75 patients with knee osteoarthritis (OA) being treated with its trial drug pentosan polysulfate sodium (PPS).
PAR

0
Paradigm Biopharmaceuticals osteoarthritis clinical trial ahead of schedule

2018-05-17 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has recruited 80% of participants for its phase IIb clinical trial in knee osteoarthritis and bone marrow lesions.
PAR

6
Paradigm Biopharmaceuticals banking on near-term revenues from repurposing FDA approved drugs

2018-05-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA-approved drug with a long track record of safely treating inflammation.
MEOBF CMXHF CSL MSB PAR MESO

0
XTEK appoints experienced investment executive to its board

2018-04-24 proactiveinvestors.com.au
XTEK Ltd (ASX:XTE) has boosted its board with the appointment of experienced investment executive Chris Fullerton as a non-executive director.
XTE PAR

0
Paradigm Biopharmaceuticals achieves pain treatment win with AFL players

2018-04-05 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is witnessing remarkable results in AFL players treated with injectable pentosan polysulfate sodium (PPS) for crippling knee, hip and groin pain.
PAR

0
Paradigm Biopharmaceuticals’ osteoarthritis trial remains ahead of schedule

2018-03-27 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd’s (ASX:PAR) phase 2b clinical trial in participants with knee osteoarthritis and concurrent bone marrow lesions is 50% recruited and remains ahead of schedule.
PAR

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...